| OAC0505 | Pragmatically approaching social network testing (SNT): using a peer-driven community outreach model to extend reach of HIV testing services (HTS) to networks of people who inject drugs (PWID) in Ukraine | Oral abstract session with live Q&A | Peer-led HIV testing strategies |
| EPE017 | Practice-based adaptive responses to overcome challenges in the scale-up of PrEP: a qualitative multiple case study of PrEP implementation in Belgian HIV clinics | E-poster | Implementation science of scaling up prevention (including PrEP) |
| EPF035 | Poverty, cumulative violence, and contexts of HIV vulnerability among refugee youth in a humanitarian setting in Uganda | E-poster | Humanitarian crises |
| PESUC32 | Potential use of pooled point-of-care HIV-1 viral load to detect HIV infection at PrEP initiation and follow-up visits in key population-led PrEP clinics in Thailand | Poster exhibition | Community-based HIV testing strategies |
| EPC133 | Potential impact of the COVID-19 pandemic on UNAIDS 95-95-95 targets in 10 Fast-Track Cities | E-poster | Monitoring and evaluation of health systems along the HIV cascade |
| EPC126 | Potential HIV-1 elite controllers in Malawian population and their impact on HIV epidemic control estimates | E-poster | Measuring HIV through population-based surveys (including the undiagnosed fraction) |
| EPB071 | Potential health benefits of integrated screening strategies for alcohol, tobacco, and other substance use, and depression, anxiety, and chronic pain among PLHIV in the United States | E-poster | Mental health (including depression and psychiatric manifestations) and HIV |
| EPC313 | Potential end-user and community-level perspectives on new biomedical HIV prevention methods in Zimbabwe | E-poster | Other new HIV prevention tools |
| OAA0402 | Potent latency reversal enables in-depth transcriptomic analyses of the HIV reservoir | Oral abstract session with live Q&A | Host cellular factors and viral mechanisms of HIV/SIV persistence and latency |
| EPA089 | Potent cytotoxic activity against SARS-CoV-2 of CD8+ T cells from individuals with HIV who received complete schedule of COVID-19 vaccines | E-poster | SARS-Cov2 vaccines |